PARP-Inhibitoren halten Einzug in die Primärtherapie des fortgeschrittenen Ovarialkarzinoms
Crossref DOI link: https://doi.org/10.1007/s15015-018-4356-5
Published Online: 2018-12-14
Published Print: 2018-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Trillsch, Fabian
Ditsch, Nina
Mahner, Sven
Text and Data Mining valid from 2018-12-01
Article History
First Online: 14 December 2018